FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W2133054529> ?p ?o ?g. }

• W2133054529 endingPage "1263" @default.
• W2133054529 startingPage "1258" @default.
• W2133054529 abstract "Background5-Fluorouracil (5-FU), doxorubicin and methotrexate (FAMTX) and cisplatin, epirubicin, leucovorin and 5-FU (PELF) have both been reported to be superior to the combination 5-FU, doxorubicin and mitomycin C (FAM) in advanced gastric carcinoma. On the basis of the presence and dose intensity of the included agents, we hypothesised that PELF would be superior to FAMTX.Patients and methodsTwo hundred patients with untreated advanced gastric carcinoma were randomised to receive PELF or FAMTX for a maximum of six cycles or until disease progression.ResultsThe complete response (CR) rates to PELF and FAMTX were, respectively, 13% [95% confidence intervals (CI) 6% to 20%] and 2% (95% CI 0% to 5%; P = 0.003), and the objective response rates [CR plus partial response (PR) rates] 39% (95% CI 29% to 49%) and 22% (95% CI 13% to 30%; P = 0.009), thus significantly favouring the PELF combination. The survival rates after 12 months (30.8% versus 22.4%) and 24 months (15.7% versus 9.5%) were also higher among patients receiving PELF, but these differences were not statistically significant. The toxicities were qualitatively different but quantitatively similar. Both regimens seem to be feasible provided that careful patient monitoring is assured.ConclusionsPELF is significantly more active than FAMTX and deserves further research in the adjuvant setting." @default.
• W2133054529 created "2016-06-24" @default.
• W2133054529 creator A5002069319 @default.
• W2133054529 creator A5015744186 @default.
• W2133054529 creator A5020732852 @default.
• W2133054529 creator A5045603955 @default.
• W2133054529 creator A5048969389 @default.
• W2133054529 creator A5052543756 @default.
• W2133054529 creator A5053569646 @default.
• W2133054529 creator A5056669813 @default.
• W2133054529 creator A5064377949 @default.
• W2133054529 creator A5066793236 @default.
• W2133054529 creator A5067892140 @default.
• W2133054529 creator A5070750504 @default.
• W2133054529 creator A5072238369 @default.
• W2133054529 creator A5080823945 @default.
• W2133054529 date "2003-08-01" @default.
• W2133054529 modified "2023-10-03" @default.
• W2133054529 title "Cisplatin, epirubicin, leucovorin and 5-fluorouracil (PELF) is more active than 5-fluorouracil, doxorubicin and methotrexate (FAMTX) in advanced gastric carcinoma" @default.
• W2133054529 cites W1843791750 @default.
• W2133054529 cites W1848862702 @default.
• W2133054529 cites W1851637255 @default.
• W2133054529 cites W1940613095 @default.
• W2133054529 cites W1981480220 @default.
• W2133054529 cites W2001281232 @default.
• W2133054529 cites W2046403414 @default.
• W2133054529 cites W2081116446 @default.
• W2133054529 cites W2088029775 @default.
• W2133054529 cites W2111513457 @default.
• W2133054529 cites W2143863553 @default.
• W2133054529 cites W2167805334 @default.
• W2133054529 cites W2261751141 @default.
• W2133054529 cites W2328993848 @default.
• W2133054529 cites W4293241248 @default.
• W2133054529 doi "https://doi.org/10.1093/annonc/mdg329" @default.
• W2133054529 hasPubMedId "https://pubmed.ncbi.nlm.nih.gov/12881389" @default.
• W2133054529 hasPublicationYear "2003" @default.
• W2133054529 type Work @default.
• W2133054529 sameAs 2133054529 @default.
• W2133054529 citedByCount "65" @default.
• W2133054529 countsByYear W21330545292012 @default.
• W2133054529 countsByYear W21330545292013 @default.
• W2133054529 countsByYear W21330545292014 @default.
• W2133054529 countsByYear W21330545292015 @default.
• W2133054529 countsByYear W21330545292016 @default.
• W2133054529 countsByYear W21330545292017 @default.
• W2133054529 countsByYear W21330545292018 @default.
• W2133054529 countsByYear W21330545292019 @default.
• W2133054529 countsByYear W21330545292021 @default.
• W2133054529 crossrefType "journal-article" @default.
• W2133054529 hasAuthorship W2133054529A5002069319 @default.
• W2133054529 hasAuthorship W2133054529A5015744186 @default.
• W2133054529 hasAuthorship W2133054529A5020732852 @default.
• W2133054529 hasAuthorship W2133054529A5045603955 @default.
• W2133054529 hasAuthorship W2133054529A5048969389 @default.
• W2133054529 hasAuthorship W2133054529A5052543756 @default.
• W2133054529 hasAuthorship W2133054529A5053569646 @default.
• W2133054529 hasAuthorship W2133054529A5056669813 @default.
• W2133054529 hasAuthorship W2133054529A5064377949 @default.
• W2133054529 hasAuthorship W2133054529A5066793236 @default.
• W2133054529 hasAuthorship W2133054529A5067892140 @default.
• W2133054529 hasAuthorship W2133054529A5070750504 @default.
• W2133054529 hasAuthorship W2133054529A5072238369 @default.
• W2133054529 hasAuthorship W2133054529A5080823945 @default.
• W2133054529 hasBestOaLocation W21330545291 @default.
• W2133054529 hasConcept C126322002 @default.
• W2133054529 hasConcept C143998085 @default.
• W2133054529 hasConcept C2776694085 @default.
• W2133054529 hasConcept C2776755627 @default.
• W2133054529 hasConcept C2778239845 @default.
• W2133054529 hasConcept C2778496288 @default.
• W2133054529 hasConcept C2780456651 @default.
• W2133054529 hasConcept C2780835546 @default.
• W2133054529 hasConcept C2781059491 @default.
• W2133054529 hasConcept C2781303535 @default.
• W2133054529 hasConcept C71924100 @default.
• W2133054529 hasConcept C90924648 @default.
• W2133054529 hasConceptScore W2133054529C126322002 @default.
• W2133054529 hasConceptScore W2133054529C143998085 @default.
• W2133054529 hasConceptScore W2133054529C2776694085 @default.
• W2133054529 hasConceptScore W2133054529C2776755627 @default.
• W2133054529 hasConceptScore W2133054529C2778239845 @default.
• W2133054529 hasConceptScore W2133054529C2778496288 @default.
• W2133054529 hasConceptScore W2133054529C2780456651 @default.
• W2133054529 hasConceptScore W2133054529C2780835546 @default.
• W2133054529 hasConceptScore W2133054529C2781059491 @default.
• W2133054529 hasConceptScore W2133054529C2781303535 @default.
• W2133054529 hasConceptScore W2133054529C71924100 @default.
• W2133054529 hasConceptScore W2133054529C90924648 @default.
• W2133054529 hasIssue "8" @default.
• W2133054529 hasLocation W21330545291 @default.
• W2133054529 hasLocation W21330545292 @default.
• W2133054529 hasOpenAccess W2133054529 @default.
• W2133054529 hasPrimaryLocation W21330545291 @default.
• W2133054529 hasRelatedWork W1526433935 @default.
• W2133054529 hasRelatedWork W1976440095 @default.
• W2133054529 hasRelatedWork W1995085324 @default.
• W2133054529 hasRelatedWork W2083924870 @default.

• next